SG Americas Securities LLC Grows Position in GRAIL, Inc. $GRAL

SG Americas Securities LLC increased its stake in shares of GRAIL, Inc. (NASDAQ:GRAL) by 304.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,920 shares of the company’s stock after acquiring an additional 8,219 shares during the quarter. SG Americas Securities LLC’s holdings in GRAIL were worth $646,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Teacher Retirement System of Texas lifted its stake in GRAIL by 5.5% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,538 shares of the company’s stock worth $439,000 after purchasing an additional 447 shares in the last quarter. Crown Wealth Group LLC increased its holdings in shares of GRAIL by 5.9% in the second quarter. Crown Wealth Group LLC now owns 8,986 shares of the company’s stock worth $462,000 after purchasing an additional 500 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of GRAIL by 28.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after buying an additional 623 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in GRAIL by 768.1% during the second quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock valued at $42,000 after buying an additional 722 shares during the last quarter. Finally, NewEdge Advisors LLC grew its holdings in GRAIL by 44.0% during the 2nd quarter. NewEdge Advisors LLC now owns 2,535 shares of the company’s stock valued at $130,000 after buying an additional 775 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on GRAL shares. Canaccord Genuity Group upped their price objective on GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Guggenheim upgraded shares of GRAIL from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Wednesday, November 12th. UBS Group set a $75.00 price target on shares of GRAIL in a research note on Friday, October 3rd. Morgan Stanley increased their price objective on shares of GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GRAIL has an average rating of “Hold” and an average price target of $97.50.

GRAIL Stock Up 14.8%

Shares of GRAL opened at $116.06 on Friday. GRAIL, Inc. has a 52-week low of $20.44 and a 52-week high of $118.84. The company has a market cap of $4.52 billion, a PE ratio of -9.98 and a beta of 4.52. The business has a fifty day moving average of $96.07 and a 200 day moving average of $67.10.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share for the quarter, beating the consensus estimate of ($3.40) by $0.94. The business had revenue of $36.19 million for the quarter, compared to the consensus estimate of $33.83 million. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. As a group, research analysts anticipate that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.